Fig. 5: ROS produced in cisplatin-treated U937-NDRG2 cells induced PKR activation. | Cell Death & Disease

Fig. 5: ROS produced in cisplatin-treated U937-NDRG2 cells induced PKR activation.

From: NDRG2 contributes to cisplatin sensitivity through modulation of BAK-to-Mcl-1 ratio

Fig. 5: ROS produced in cisplatin-treated U937-NDRG2 cells induced PKR activation.The alternative text for this image may have been generated using AI.

a U937-Mock and U937-NDRG2 cells were treated with cisplatin, and then the level of ROS was determined using DCFH-DA staining. b, c U937-NDRG2 cells were treated with cisplatin in the presence or absence of a ROS scavenger, NAC (10 μM). Apoptosis and the mitochondrial potential were analyzed using flow cytometry. d Levels of the indicated proteins were determined by immunoblotting. Ctrl: vehicle-treated group. ***p < 0.005 by t-test. Data are presented as mean ± SEM

Back to article page